Insider Selling: Amphastar Pharmaceuticals Inc (AMPH) Insider Sells 10,000 Shares of Stock

Share on StockTwits

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) insider Jason B. Shandell sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $21.97, for a total value of $219,700.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

NASDAQ AMPH traded up $0.23 on Friday, hitting $22.16. 2,602 shares of the stock traded hands, compared to its average volume of 185,910. Amphastar Pharmaceuticals Inc has a 12 month low of $14.40 and a 12 month high of $25.43. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of 105.50 and a beta of 1.37. The company has a current ratio of 2.06, a quick ratio of 1.41 and a debt-to-equity ratio of 0.09.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Tuesday, March 12th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. Amphastar Pharmaceuticals had a positive return on equity of 3.17% and a negative net margin of 1.96%. The business had revenue of $89.69 million during the quarter, compared to analyst estimates of $75.46 million. Analysts forecast that Amphastar Pharmaceuticals Inc will post 0.35 EPS for the current year.

A number of brokerages have recently issued reports on AMPH. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 24th. Needham & Company LLC lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating and set a $22.20 price objective for the company. in a report on Wednesday, March 13th. TheStreet lowered Amphastar Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Monday, March 18th. BidaskClub raised Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, March 3rd. Finally, Piper Jaffray Companies lowered Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $24.00 to $23.00 in a report on Wednesday, March 13th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Amphastar Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $23.73.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers lifted its position in shares of Amphastar Pharmaceuticals by 18.3% during the fourth quarter. Rhumbline Advisers now owns 103,943 shares of the company’s stock worth $2,068,000 after acquiring an additional 16,080 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Amphastar Pharmaceuticals by 104.3% during the third quarter. Renaissance Technologies LLC now owns 186,100 shares of the company’s stock worth $3,581,000 after acquiring an additional 95,000 shares in the last quarter. MetLife Investment Advisors LLC lifted its position in shares of Amphastar Pharmaceuticals by 54.3% during the third quarter. MetLife Investment Advisors LLC now owns 28,086 shares of the company’s stock worth $540,000 after acquiring an additional 9,881 shares in the last quarter. Rothschild & Co. Asset Management US Inc. lifted its position in shares of Amphastar Pharmaceuticals by 4.3% during the fourth quarter. Rothschild & Co. Asset Management US Inc. now owns 335,930 shares of the company’s stock worth $6,685,000 after acquiring an additional 13,757 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Amphastar Pharmaceuticals by 3.6% during the third quarter. Legal & General Group Plc now owns 74,224 shares of the company’s stock worth $1,425,000 after acquiring an additional 2,568 shares in the last quarter. 47.37% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Amphastar Pharmaceuticals Inc (AMPH) Insider Sells 10,000 Shares of Stock” was published by Week Herald and is the property of of Week Herald. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://weekherald.com/2019/05/03/insider-selling-amphastar-pharmaceuticals-inc-amph-insider-sells-10000-shares-of-stock.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Further Reading: Dividend

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.